These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 30655313)

  • 1. Unfolding the Role of Calreticulin in Myeloproliferative Neoplasm Pathogenesis.
    Merlinsky TR; Levine RL; Pronier E
    Clin Cancer Res; 2019 May; 25(10):2956-2962. PubMed ID: 30655313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanism underlying the development of myeloproliferative neoplasms through mutant calreticulin.
    Edahiro Y; Araki M; Komatsu N
    Cancer Sci; 2020 Aug; 111(8):2682-2688. PubMed ID: 32462673
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants.
    Chachoua I; Pecquet C; El-Khoury M; Nivarthi H; Albu RI; Marty C; Gryshkova V; Defour JP; Vertenoeil G; Ngo A; Koay A; Raslova H; Courtoy PJ; Choong ML; Plo I; Vainchenker W; Kralovics R; Constantinescu SN
    Blood; 2016 Mar; 127(10):1325-35. PubMed ID: 26668133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutant calreticulin in myeloproliferative neoplasms.
    How J; Hobbs GS; Mullally A
    Blood; 2019 Dec; 134(25):2242-2248. PubMed ID: 31562135
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Defining the requirements for the pathogenic interaction between mutant calreticulin and MPL in MPN.
    Elf S; Abdelfattah NS; Baral AJ; Beeson D; Rivera JF; Ko A; Florescu N; Birrane G; Chen E; Mullally A
    Blood; 2018 Feb; 131(7):782-786. PubMed ID: 29288169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. JAK-STAT signaling in the therapeutic landscape of myeloproliferative neoplasms.
    O'Sullivan JM; Harrison CN
    Mol Cell Endocrinol; 2017 Aug; 451():71-79. PubMed ID: 28167129
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Calreticulin-mutant proteins induce megakaryocytic signaling to transform hematopoietic cells and undergo accelerated degradation and Golgi-mediated secretion.
    Han L; Schubert C; Köhler J; Schemionek M; Isfort S; Brümmendorf TH; Koschmieder S; Chatain N
    J Hematol Oncol; 2016 May; 9(1):45. PubMed ID: 27177927
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A primer on genomic and epigenomic alterations in the myeloproliferative neoplasms.
    Rampal R; Levine RL
    Best Pract Res Clin Haematol; 2014 Jun; 27(2):83-93. PubMed ID: 25189720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Somatic mutations of calreticulin in myeloproliferative neoplasms.
    Imai M; Araki M; Komatsu N
    Int J Hematol; 2017 Jun; 105(6):743-747. PubMed ID: 28470469
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation of the thrombopoietin receptor by mutant calreticulin in CALR-mutant myeloproliferative neoplasms.
    Araki M; Yang Y; Masubuchi N; Hironaka Y; Takei H; Morishita S; Mizukami Y; Kan S; Shirane S; Edahiro Y; Sunami Y; Ohsaka A; Komatsu N
    Blood; 2016 Mar; 127(10):1307-16. PubMed ID: 26817954
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutant Calreticulin Requires Both Its Mutant C-terminus and the Thrombopoietin Receptor for Oncogenic Transformation.
    Elf S; Abdelfattah NS; Chen E; Perales-Patón J; Rosen EA; Ko A; Peisker F; Florescu N; Giannini S; Wolach O; Morgan EA; Tothova Z; Losman JA; Schneider RK; Al-Shahrour F; Mullally A
    Cancer Discov; 2016 Apr; 6(4):368-81. PubMed ID: 26951227
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel molecular mechanism of cellular transformation by a mutant molecular chaperone in myeloproliferative neoplasms.
    Araki M; Komatsu N
    Cancer Sci; 2017 Oct; 108(10):1907-1912. PubMed ID: 28741795
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validation of a molecular diagnostic assay for CALR exon 9 indels in myeloproliferative neoplasms: identification of coexisting JAK2 and CALR mutations and a novel 9 bp deletion in CALR.
    Murugesan G; Guenther-Johnson J; Mularo F; Cook JR; Daly TM
    Int J Lab Hematol; 2016 Jun; 38(3):284-97. PubMed ID: 27018326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis.
    Rampal R; Al-Shahrour F; Abdel-Wahab O; Patel JP; Brunel JP; Mermel CH; Bass AJ; Pretz J; Ahn J; Hricik T; Kilpivaara O; Wadleigh M; Busque L; Gilliland DG; Golub TR; Ebert BL; Levine RL
    Blood; 2014 May; 123(22):e123-33. PubMed ID: 24740812
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CALR, JAK2 and MPL mutation status in Argentinean patients with BCR-ABL1- negative myeloproliferative neoplasms.
    Ojeda MJ; Bragós IM; Calvo KL; Williams GM; Carbonell MM; Pratti AF
    Hematology; 2018 May; 23(4):208-211. PubMed ID: 28990497
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CALR mutations in a cohort of JAK2 V617F negative patients with suspected myeloproliferative neoplasms.
    Belcic Mikic T; Pajic T; Sever M
    Sci Rep; 2019 Dec; 9(1):19838. PubMed ID: 31882869
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Upregulation of endogenous thrombopoietin receptor (MPL) with in vivo passage of calreticulin (CALR) mutant Ba/F3 cells, highlighting MPL as the requisite cytokine receptor for CALR mediated transformation.
    Brooks SA; Kim DM; Morse SJ; Nguyen QH; Craver BM; Lai HY; Fleischman AG
    Leuk Res; 2019 Jul; 82():11-14. PubMed ID: 31128484
    [No Abstract]   [Full Text] [Related]  

  • 18. Pathogenesis of myeloproliferative neoplasms.
    Skoda RC; Duek A; Grisouard J
    Exp Hematol; 2015 Aug; 43(8):599-608. PubMed ID: 26209551
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable.
    Kim SY; Im K; Park SN; Kwon J; Kim JA; Lee DS
    Am J Clin Pathol; 2015 May; 143(5):635-44. PubMed ID: 25873496
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CALR gene mutational profile in myeloproliferative neoplasms with non-mutated JAK2 in Moroccan patients: A case series and germline in-frame deletion.
    Smaili W; Doubaj Y; Laarabi FZ; Lyahyai J; Kerbout M; Mikdame M; Sefiani A
    Curr Res Transl Med; 2017; 65(1):15-19. PubMed ID: 28340692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.